Clinical trials and analysis to support lapatinib as a combination agent for advanced breast cancer. The widespread adoption of lapatinib as a combination agent for advanced breast cancer hinged on the detailed analysis of sub-groups led by Professor David Cameron and the Cancer Research UK Edinburgh Centre. Helping Introduce New Breast Cancer Therapy To The Global Market (391.9 KB PDF) This article was published on 2024-09-23
